[1] Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis[J]. Nat Rev Rheumatol,2010,6(7):399-405. [2] Braun J, Sieper J. Ankylosing spondylitis[J]. Lancet,2007,369(9570):1379-1390. [3] 戴冽,汤美安,尹培达,等.强直性脊柱炎的脊柱外表现[J].中华风湿病学杂志,1998,2(3):168-168. [4] Benedek TG. How did ankylosing spondylitis become aseparate disease[J] ? Clin Exp Rheumatol,2009,27(4 Suppl 55):S3-S9. [5] Glinka A, Wu W,Delius H, et al.Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction[J]. Nature,1998, 391(6665):357-362. [6] Kwon SR, Lim MJ, Suh CH, et al.Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy[J]. Rheumatol Int,2012,32(8):2523-2527. [7] Appel H,Ruiz-Heiland G,Listing J,et al.Altered skeletal expression of sclerostin and its link toradiographic progression in ankylosing spondylitis[J]. Arthritis Rheum,2009,60:3257-3262. [8] Bonewald LF,Johnson ML.Ostepcytes,mechanosensing and Wnt signaling[J].Bone,2008,42(4):606-615. [9] Wanders A,Heijde D, Landewe R,et al.Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis:a randomized clinical trial[J]. Arthritis Rheum,2005,52(6):1756-1765. [10] 李建明,初同伟,周跃.BMP-2和bFGF在强直性脊柱炎活动期骶髂关节滑膜组织中的表达[J].第三军医大学学报,2008,30(3):25l-253. [11] Liu T, Gao Y, Sakamoto K et al.BMP-2 promotes differentiation of osteblasts and chondroblasts in Runx2-deficient cell lines[J].J Cell Physiol,2007,211(3):728-735. [12] Lories RJ,Luyten FP, de Vlam K. Progress in spondyloarthritis. Mechanisms of new bone formation in spondyloarthritis[J]. Arthitis Res Ther,2009,11(2):221. [13] Uderhardt S, Diarra D, Katzenbeisser J,et al. Blockade of Dickkopf(DKK)-1 induces fusion of sacroiliac joints[J]. Ann Rheum Dis,2010,69(3):592-597. [14] Cruickshank B.Lesions of cartilaginous joints in ankylosing spondylitis[J].J Pathol Bacteriol,1956,71(1):73-84. [15] Sieper J, Appel H, Braun J, et al. Critical appraisal of assessment of structural damage in ankylosing spondylitis:implications for treatment outcomes[J]. Arthritis Rheum,2008,58(3):649-656. [16] Lories RJU, Derses I, Geuppens JL, et al. Bone morphogenetic proteins 2 and 6,expressed in arthritic synovium,are regulated by proinflammatory cytokines and differentially modulate fibroblast like synoviocyte apptosis[J]. Arthritis Rheum,2003,48(10):2807-2818. [17] Fukui N, Zhu Y, Maloney WJ, et al. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1and TNF-alpha in normal and osteoarthritic chondrocytes[J]. J Bone Joint Surg(Am),2003,85A Suppl 3:59-66. [18] Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis[J]. Arthritis Res Ther,2008,10(5):R104. [19] Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 years oftreatment with the anti-TNF-alpha antibody infliximab[J]. Rheumatology(Oxford),2007,46(9):1450-1453. [20] Lories RJ, Derses I,de Bari C,et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis[J]. Arthritis Rheum,2007,56(2):489-497. [21] McGonagle D,Wakefield RJ, Tan AL, et al. Distinct topography of erosion and new bone formation in achilles tendon enthesitis:implications for understanding the link between inflammation and bone formation in spondylarthritis[J]. Arthritis Rheum,2008,58(9):2694-2699. [22] Van der Heijde D, Landewe R, Einstei S,et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept[J]. Arthritis Rheum,2008,58(5):1324-1331. [23] Van der Heijde D, Landewe R, Baraliakos X,et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis[J]. Arthritis Rheum,2008,58(10):3063-3070. [24] Van der Heijde D, Landewe R, Maksymowych W,et al. Adalimumab(HUMIRA)therapy for ankylosing spondylitis over 2 years does not demonstrate inhibition of radiographic progression compared with a historical control group[J]. Arthritis Rheum,2008,58:S413. [25] Roux S, Orcel P. Bone loss factors that regulate osteoclast differentiation: an update[J].Arthritis Res,2000,2(6):451-456. [26] Chiowchanwisawaki P,Pedersen SJ,Lambert R,et a1.Presentation:resolution of inflammation following treatment of ankylosing spondylitis with anti-TNF agents is associated with new bone formation[C].Philadelphia:2009 ACR/ARHP Scientific meeting,2009:1257. [27] Maksymowych WP, Chiowchanwisawakit P, Clare T,et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis:evidence of a relationship between inflammation and new bone formation[J]. Arthritis Rheum,2009,60(1):93-102. [28] 雷鹏真,危国军,裴孝鹏,等.Dickkopf-1在强直性脊柱炎病理过程作用研究进展[J].中华实用诊断与治疗杂志,2012,26(12):1149-1151. |